Literature DB >> 30373692

Polysomnographic Sleep Disturbances Due to High-Dose Zolpidem Use: A Case Report.

Hayato Ohshima1, Nozomu Kotorii1, Minoru Takii1, Hiroshi Hiejima1, Mitsunari Habukawa1, Hiroo Kuwahara1, Naohisa Uchimura1.   

Abstract

ABSTRACT: Zolpidem is widely prescribed for the treatment of insomnia and is used to both induce and maintain sleep. Previously, zolpidem was thought to have low abuse potential; however, several reports have documented dose escalation and abuse in the past two decades. Here, we report the case of a patient with high-dose zolpidem dependence who underwent polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT). The patient, a 29-year-old man, was administered zolpidem at doses of 300 to 1,200 mg/day, but he abused zolpidem to feel energetic. Consequently, he had a car accident while on a high dose, which the PSG revealed caused activation instead of sedation. The MSLT showed excessive daytime sleepiness despite a lack of subjective sleepiness under this condition. Our findings suggest that disrupted sleep and daytime sleepiness caused by supratherapeutic zolpidem doses could place individuals at high risk for accidents, including those who are unaware of sleepiness.
© 2018 American Academy of Sleep Medicine.

Entities:  

Keywords:  abused; polysomnography; zolpidem

Mesh:

Substances:

Year:  2018        PMID: 30373692      PMCID: PMC6223559          DOI: 10.5664/jcsm.7500

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  7 in total

1.  Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep.

Authors:  K Honda; J Riehl; E Mignot; S Nishino
Journal:  Neuroreport       Date:  1999-11-26       Impact factor: 1.837

2.  An automatic sleep-stage analysis system with off-line high-speed processing using a super mini-computer.

Authors:  H Kuwahara; M Tanaka; Y Mizuki; M Suetsugi
Journal:  Kurume Med J       Date:  1996

Review 3.  An update on zolpidem abuse and dependence.

Authors:  Caroline Victorri-Vigneau; Marie Gérardin; Morgane Rousselet; Marylène Guerlais; Marie Grall-Bronnec; Pascale Jolliet
Journal:  J Addict Dis       Date:  2014

4.  Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.

Authors:  Stephanie C Licata; Yasmin Mashhoon; Robert R Maclean; Scott E Lukas
Journal:  Behav Pharmacol       Date:  2011-04       Impact factor: 2.293

Review 5.  Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.

Authors:  G Hajak; W E Müller; H U Wittchen; D Pittrow; W Kirch
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

Review 6.  Recovery of consciousness after brain injury: a mesocircuit hypothesis.

Authors:  Nicholas D Schiff
Journal:  Trends Neurosci       Date:  2009-12-01       Impact factor: 13.837

7.  Neural bases for addictive properties of benzodiazepines.

Authors:  Kelly R Tan; Matthew Brown; Gwenaël Labouèbe; Cédric Yvon; Cyril Creton; Jean-Marc Fritschy; Uwe Rudolph; Christian Lüscher
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

  7 in total
  2 in total

1.  'Z-trip'? A Comprehensive Overview and a Case-series of Zolpidem Misuse.

Authors:  Laura Orsolini; Stefania Chiappini; Paolo Grandinetti; Angelo Bruschi; Roberta Testa; Alessandra Provenzano; Domenico De Berardis; Umberto Volpe
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

2.  Zolpidem withdrawal seizure in an Iranian young woman: A case presentation.

Authors:  Pezhman Hadinezhad; Seyed Hamzeh Hosseini
Journal:  Caspian J Intern Med       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.